| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MTA1 |
| Uniprot No | Q13330 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-715aa |
| 氨基酸序列 | MAANMYRVGD YVYFENSSSN PYLIRRIEEL NKTANGNVEA KVVCFYRRRD ISSTLIALAD KHATLSVCYK AGPGADNGEE GEIEEEMENP EMVDLPEKLK HQLRHRELFL SRQLESLPAT HIRGKCSVTL LNETESLKSY LEREDFFFYS LVYDPQQKTL LADKGEIRVG NRYQADITDL LKEGEEDGRD QSRLETQVWE AHNPLTDKQI DQFLVVARSV GTFARALDCS SSVRQPSLHM SAAAASRDIT LFHAMDTLHK NIYDISKAIS ALVPQGGPVL CRDEMEEWSA SEANLFEEAL EKYGKDFTDI QQDFLPWKSL TSIIEYYYMW KTTDRYVQQK RLKAAEAESK LKQVYIPNYN KPNPNQISVN NVKAGVVNGT GAPGQSPGAG RACESCYTTQ SYQWYSWGPP NMQCRLCASC WTYWKKYGGL KMPTRLDGER PGPNRSNMSP HGLPARSSGS PKFAMKTRQA FYLHTTKLTR IARRLCREIL RPWHAARHPY LPINSAAIKA ECTARLPEAS QSPLVLKQAV RKPLEAVLRY LETHPRPPKP DPVKSVSSVL SSLTPAKVAP VINNGSPTIL GKRSYEQHNG VDGNMKKRLL MPSRGLANHG QARHMGPSRN LLLNGKSYPT KVRLIRGGSL PPVKRRRMNW IDAPDDVFYM ATEETRKIRK LLSSSETKRA ARRPYKPIAL RQSQALPPRP PPPAPVNDEP IVIED |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MTA1重组蛋白的模拟参考文献示例(注：以下内容为假设性示例，建议通过PubMed、Google Scholar等平台核实真实文献)：
---
1. **文献名称**: *"Expression and purification of recombinant MTA1 protein for functional studies in breast cancer"*
**作者**: Li, X., et al.
**摘要**: 研究报道了通过大肠杆菌系统成功表达并纯化MTA1重组蛋白，验证了其与组蛋白去乙酰化酶(HDAC)的结合能力，并发现其在乳腺癌细胞中促进侵袭的分子机制。
2. **文献名称**: *"Structural insights into MTA1-mediated gene repression via recombinant protein crystallography"*
**作者**: Patel, R., & Kumar, S.
**摘要**: 利用重组MTA1蛋白进行X射线晶体学分析，揭示了MTA1与NuRD复合物相互作用的关键结构域，阐明了其在染色质重塑和基因沉默中的作用。
3. **文献名称**: *"MTA1 recombinant protein enhances epithelial-mesenchymal transition (EMT) in vitro"*
**作者**: Wang, Y., et al.
**摘要**: 通过体外实验证明，外源性添加MTA1重组蛋白可激活TGF-β信号通路，促进EMT相关标志物(如E-cadherin下调、Vimentin上调)，提示其在肿瘤转移中的直接作用。
4. **文献名称**: *"Development of a high-throughput screening assay for MTA1 inhibitors using recombinant protein"*
**作者**: Smith, J., et al.
**摘要**: 研究构建了基于MTA1重组蛋白的荧光偏振筛选平台，成功鉴定出多个小分子抑制剂，为靶向MTA1的抗癌药物开发提供新策略。
---
建议通过以下关键词在学术数据库中检索真实文献：
**"MTA1 recombinant protein expression"**, **"MTA1 structural analysis"**, **"MTA1 cancer metastasis"**。
MTA1 (Metastasis-associated protein 1) is a critical member of the MTA family of chromatin-regulatory proteins, first identified in 1993 for its overexpression in metastatic cancer cells. It functions as a transcriptional coregulator within the Nucleosome Remodeling and Histone Deacetylation (NuRD) complex, modulating gene expression through epigenetic mechanisms such as histone deacetylation. MTA1 interacts with histone deacetylases (HDACs) and other chromatin modifiers to repress or activate target genes, influencing processes like DNA repair, cell proliferation, and epithelial-mesenchymal transition (EMT). Its role in cancer progression—particularly in metastasis, angiogenesis, and therapy resistance—has been extensively studied, with elevated MTA1 levels linked to poor prognosis in multiple cancers, including breast, prostate, and gastrointestinal malignancies.
Structurally, MTA1 contains conserved domains (e.g., BAH, ELM2. SANT) that mediate protein-protein interactions and chromatin binding. Recombinant MTA1 proteins are engineered to study these interactions and functional mechanisms in vitro. Typically produced in bacterial (e.g., *E. coli*) or mammalian expression systems, recombinant MTA1 retains the ability to integrate into the NuRD complex and regulate HDAC activity. Researchers employ it to dissect signaling pathways (e.g., Wnt, hypoxia-inducible factor), screen for inhibitors, or analyze post-translational modifications (e.g., phosphorylation, acetylation) that modulate its stability and oncogenic activity. Its applications extend to structural studies (crystallography, cryo-EM) and developing targeted therapies to disrupt MTA1-associated oncogenic networks. Despite challenges in maintaining native conformation during purification, recombinant MTA1 remains a vital tool for unraveling its dual roles in both physiological processes and disease pathogenesis.
×
